Zhejiang Jiuzhou Pharmaceutical (603456.SH): The application for listing of p-toluenesulfonic acid edaravone chemical raw materials has been approved.
Jiu Zhou Pharmaceutical (603456.SH) announced that the company has received a notice issued by the National Medical Products Administration regarding the approval of methanesulfonic acid...
Zhejiang Jiuzhou Pharmaceutical (603456.SH) announced that the company has received the "Chemical raw material drug market application approval letter" for the compound benzenesulfonic acid edoxaban from the National Medical Products Administration. Benzenesulfonic acid edoxaban is an oral anticoagulant used primarily to prevent strokes and systemic embolism in patients with non-valvular atrial fibrillation, as well as to treat or prevent deep vein thrombosis and pulmonary embolism.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
